Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 241 to 247 of 247 results for carcinoma

  1. Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27)

    Evidence-based recommendations on using immunohistochemistry or microsatellite instability testing to guide further testing for Lynch syndrome in people with colorectal cancer

  2. Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)

    Evidence-based recommendations on cobimetinib (Cotellic) with vemurafenib (Zelboraf) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.

  3. Aixplorer ShearWave Elastography for ultrasound imaging and assessing suspicious breast lesions (MIB15)

    NICE has developed a Medtech Innovation Briefing (MIB) on Aixplorer ShearWave Elastography for ultrasound imaging and assessing suspicious breast lesions

  4. New combination treatment for patients with advanced kidney cancer

    Adults with advanced renal cell carcinoma can now be offered avelumab with axitinib as a first line treatment option on the Cancer Drugs Fund (CDF), NICE has said in final draft guidance.

  5. More than 100 people a year in England could benefit from new endometrial cancer treatment within the Cancer Drugs Fund

    Innovative new drug for treating endometrial cancer in adults recommended by NICE as an option for use within the Cancer Drugs Fund

  6. Hundreds of people set to benefit as NICE recommends selective internal radiation therapy for treating advanced liver cancer

    Hundreds of people with advanced liver cancer (also called hepatocellular carcinoma or HCC) are set to benefit after NICE today (26 February 2021) published final draft guidance recommending a cancer treatment called selective internal radiation therapy (SIRT) as an option for treating the condition

  7. People with advanced or metastatic urothelial cancer to get life-extending treatment

    Around 130 people per year with untreated locally advanced or metastatic urothelial cancer will be eligible for a new life-extending treatment after NICE published final draft guidance today (30 September 2021) recommending atezolizumab.